Use of Surrogate Measures in Cost-Effectiveness Analyses of Lipid-Lowering Therapies

Value in Health

Volumn 1, Issue 3, 1998, Pages 175-180

  Delea, Thomas E ^a  

^a POLICY ANALYSIS INC PAI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1542571111     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.1998.130175.x     Document Type: Conference Paper

References (20)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-9.
2. Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
3. Caro J, Klittich W, Mcguire A, et al. The West of Scotland Coronary Prevention Study: economic benefit analysis of primary prevention with pravastatin. Br Med J 1997;315:1577-82.
4. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336:332-6.
5. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251(3):365-74.
6. Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 1995;91:2274-82.
7. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997;278:313-21.
8. Shepherd J, Park JS. Prevention of heart disease: is LDL reduction the outcome of choice? No, there is more. Value Health 1998;1(2):120-4.
9. Schulman KA, Kinosian B, Jacobson TA, et al. Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA 1990;264:3025-33.
10. Delea TE, Hogan TJ, Gasper MC, McGarry LJ, Oster G. Cost-effectiveness of cholesterol lowering drugs: a re-examination of treatment alternatives. Unpublished manuscript.
11. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
12. Coronary Drug Project Research Group. The Coronary Drug Project: findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA 1972;220:996-1008.
13. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251(3):351-64.
14. Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. Br Med J 1971;4:775-84.
15. Dayton S, Pearce ML, Hashimoto S, et al. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969;40(Suppl 2):1-63.
16. Research Committee to the Medical Research Council. Low-fat diet in myocardial infarction - a controlled trial. Lancet 1965;2:501-4.
17. Research Committee to the Medical Research Council. Controlled trial of soya-bean oil in myocardial infarction. Lancet 1968;2:693-700.
18. Group of Physicians of the Newcastle Upon Tyne Region. Trial of clofibrate in the treatment of ischaemic heart disease. Br Med J 1971;4:767-75.
19. Leren P. The Oslo Diet Heart Study: eleven-year report. Circulation 1970;42:935-42.
20. Committee of Principal Investigators. WHO Clofibrate Trial: a cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-118.